<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518606</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0101/1709</org_study_id>
    <secondary_id>2017-001857-14</secondary_id>
    <nct_id>NCT03518606</nct_id>
  </id_info>
  <brief_title>Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours</brief_title>
  <acronym>MOVIE</acronym>
  <official_title>A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II national, multicentre, multiple cohort, prospective open-label,&#xD;
      non-randomised and non-comparative study, to evaluate the safety and activity of metronomic&#xD;
      oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy for the&#xD;
      treatment of advanced solid tumours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
      The study divided in two parts:&#xD;
&#xD;
        -  Phase I part: dose escalation study of metronomic oral vinorelbine associated with&#xD;
           durvalumab + tremelimumab combination immunotherapy,&#xD;
&#xD;
        -  Phase II part: activity study of metronomic oral vinorelbine associated with durvalumab&#xD;
           + tremelimumab combination immunotherapy.&#xD;
&#xD;
      Indication:&#xD;
&#xD;
      Patient eligible to the study are patients with histologically confirmed locally advanced or&#xD;
      metastatic solid tumours, resistant to conventional therapies, and candidate to experimental&#xD;
      therapy by local clinical board, from the following primary tumours: head and neck, prostate,&#xD;
      cervix, and breast cancers, as well as miscellaneous malignancies with high mutational load.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase I/II national, multicentre, multiple cohort, prospective open-label, non-randomised and non-comparative study divided in two parts:&#xD;
Phase I part: dose escalation study of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy,&#xD;
Phase II part: activity study of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and the phase II recommended dose (RP2D)</measure>
    <time_frame>9 months</time_frame>
    <description>Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CBR-24week</measure>
    <time_frame>24 months</time_frame>
    <description>Phase II</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Advanced Solid Tumours</condition>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Cervix Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients presenting advanced refractory breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and neck cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients presenting advanced refractory head and neck cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervix cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients presenting advanced refractory cervix cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients presenting advanced refractory prostate cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Miscellaneous cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients presenting advanced refractory solid tumour with high mutational load</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab + Tremelimumab + metronomic Vinorelbine</intervention_name>
    <description>Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy</description>
    <arm_group_label>Breast cancer cohort</arm_group_label>
    <arm_group_label>Cervix cohort</arm_group_label>
    <arm_group_label>Head and neck cohort</arm_group_label>
    <arm_group_label>Miscellaneous cohort</arm_group_label>
    <arm_group_label>Prostate cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have signed a written informed consent form prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
          2. Histologically confirmed locally advanced or metastatic solid tumours, resistant to&#xD;
             conventional therapies, and candidate to experimental therapy by local clinical board,&#xD;
             from the following primary tumours:&#xD;
&#xD;
               -  Head and neck squamous cell carcinomas,&#xD;
&#xD;
               -  Breast cancer,&#xD;
&#xD;
               -  Prostate cancer,&#xD;
&#xD;
               -  Cervical cancer,&#xD;
&#xD;
               -  Miscellaneous primary tumours (except melanoma, non-small cell lung cancer&#xD;
                  [NSCLC], and renal cell cancer) with a high mutational load, as defined by a&#xD;
                  molecular clinical board after next-generation sequencing (comprehensive cancer&#xD;
                  gene panel or whole genome/exome sequencing) analysis.&#xD;
&#xD;
          3. Patients aged ≥18 years at registration.&#xD;
&#xD;
          4. Life expectancy ≥3 months.&#xD;
&#xD;
          5. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             v1.1.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.&#xD;
&#xD;
          7. Body weight &gt;30 kg.&#xD;
&#xD;
          8. Normal haematological function (ANC ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L;&#xD;
             haemoglobin ≥9.0 g/dL).&#xD;
&#xD;
          9. Normal hepatic function: total bilirubin ≤1.5 upper limit of normal (ULN) (unless&#xD;
             documented Gilbert's syndrome); asparate aminotransferase (ASAT) and alanine&#xD;
             aminotransferase (ALAT) ≤2.5 ULN (≤5 ULN in the presence of liver metastases).&#xD;
&#xD;
         10. Normal cardiac function: left ventricular ejection fraction (LVEF) ≥50% (any&#xD;
             assessment method).&#xD;
&#xD;
         11. Measured Creatinine clearance (Cockcroft and Gault) ≥40 mL/min OR creatinine ≤1.5&#xD;
             times ULN.&#xD;
&#xD;
         12. Evidence of post-menopausal status or negative urinary or serum pregnancy test for&#xD;
             female pre-menopausal patients (urine within 72 hours, or serum pregnancy test within&#xD;
             14 days prior to enrolment).&#xD;
&#xD;
         13. Patient willing and able to comply with the protocol for the duration of the study&#xD;
             including: treatment and scheduled visits during the treatment phase, and visits&#xD;
             during follow up.&#xD;
&#xD;
         14. Patient is willing to comply with a baseline tumour biopsy (unless an archived biopsy&#xD;
             of a secondary or a primary site of the current disease-collected within 3 months&#xD;
             prior enrolment is available for research ; bone metastasis are accepted only when&#xD;
             predominant extra-bone tissue is available), and with a series of blood samples&#xD;
             throughout the study.&#xD;
&#xD;
         15. Patient must be affiliated to a social health insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other concurrent malignancies, except adequately treated cone-biopsied in situ&#xD;
             carcinoma of the cervix, or basal cell or squamous cell carcinoma of the skin.&#xD;
             Patients who have had potentially curative therapy for a prior malignancy are eligible&#xD;
             provided there has been no evidence of disease for ≥5 years and the risk of recurrence&#xD;
             is considered low.&#xD;
&#xD;
          2. Active brain metastases, spinal cord compression, or leptomeningeal disease. Patients&#xD;
             whose brain metastases have been treated may participate if the brain metastases are&#xD;
             stable by imagery (defined as 2 brain images, both obtained after treatment of the&#xD;
             brain metastases and at least four weeks apart, and showing no evidence of&#xD;
             intracranial progression). In addition, any neurologic symptoms caused by the brain&#xD;
             metastases or their treatment must be resolved or stable, without steroidal treatment&#xD;
             or with a dose of steroid ≤10 mg/day of prednisone or its equivalent and an&#xD;
             anticonvulsants, for at least 14 days prior to the start of treatment.&#xD;
&#xD;
          3. Previous treatment with an anti-PD1/PD-L1 including durvalumab or an anti-CTLA-4&#xD;
             therapy including tremelimumab or vinorelbine.&#xD;
&#xD;
          4. Patients with known allergy or severe hypersensitivity to any of the study treatments&#xD;
             or any of the study treatment excipients.&#xD;
&#xD;
          5. History of active primary immunodeficiency.&#xD;
&#xD;
          6. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               -  Patients with vitiligo or alopecia.&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement therapy.&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy.&#xD;
&#xD;
               -  Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician.&#xD;
&#xD;
               -  Patients with celiac disease controlled by diet alone.&#xD;
&#xD;
          7. History of allogeneic organ transplantation.&#xD;
&#xD;
          8. History or evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
          9. Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and tuberculosis testing in&#xD;
             line with local practice), hepatitis B (known positive hepatitis B virus (HBV) surface&#xD;
             antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV&#xD;
             1/2 antibodies). Patients with a past or resolved HBV infection (defined as the&#xD;
             presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg) are eligible.&#xD;
             Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain&#xD;
             reaction is negative for HCV RNA.&#xD;
&#xD;
         10. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab or tremelimumab. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection)&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or its&#xD;
                  equivalent&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
&#xD;
         11. Uncontrolled intercurrent illness, including but not limited to, symptomatic&#xD;
             congestive heart failure, uncontrolled hypertension, unstable angina pectoris,&#xD;
             clinically significant cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring adverse events, or compromise the ability of the patient to give&#xD;
             written informed consent&#xD;
&#xD;
         12. Patients who have received a live vaccine within 30 days of the planned start of the&#xD;
             study treatment(s).&#xD;
&#xD;
         13. Prior anticancer therapy, within the last 3 weeks. It includes radiotherapy&#xD;
             (concurrent palliative radiotherapy is allowed), endocrine therapy, immunotherapy,&#xD;
             chemotherapy (2 weeks for weekly schedule, 6 weeks for nitrosoureas and mitomycin C),&#xD;
             or other investigational agents.&#xD;
&#xD;
         14. Major surgery within 28 days prior to the first dose of study treatment. Note: Local&#xD;
             surgery of isolated lesions for palliative intent is acceptable.&#xD;
&#xD;
         15. Malabsorption syndrome or disease significantly affecting gastro-intestinal function&#xD;
             or major resection of the stomach or proximal small bowel that could affect absorption&#xD;
             of oral vinorelbine&#xD;
&#xD;
         16. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
&#xD;
               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after&#xD;
                  consultation with the Study Coordinator.&#xD;
&#xD;
               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab or tremelimumab may be included only after consultation&#xD;
                  with the Study Coordinator.&#xD;
&#xD;
         17. Patients enrolled in another clinical study with an investigational product within 30&#xD;
             days of inclusion.&#xD;
&#xD;
         18. Concurrent enrolment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or during the follow-up period of an&#xD;
             interventional study&#xD;
&#xD;
         19. Female patients who are pregnant or breastfeeding. Male or female patients of&#xD;
             reproductive potential who are not willing to employ highly effective methods of&#xD;
             contraception from screening to 180 days after receipt of the final dose of durvalumab&#xD;
             and tremelimumab in combination or 90 days after the last dose of durvalumab&#xD;
             monotherapy or vinorelbine.&#xD;
&#xD;
         20. Persons deprived of their liberty or under protective custody or guardianship.&#xD;
&#xD;
         21. Patients with any psychological, family, sociological or geographical problem&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumours</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Tremelimumab</keyword>
  <keyword>Metronomic vinorelbine</keyword>
  <keyword>High mutational load malignancies</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Early phase</keyword>
  <keyword>Combination study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

